COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

23.81

Decreased from previous period

OCF/share above 1.5x 3141.T's 9.88. David Dodd would verify if a competitive edge drives superior cash generation.

Free Cash Flow per Share

3.66

Decreased from previous period

FCF/share above 1.5x 3141.T's 1.66. David Dodd would confirm if a strong moat leads to hefty cash flow.

Capex-to-Operating Cash Flow

84.62%

Increased from previous period

Similar Capex/OCF to 3141.T's 83.22%. Walter Schloss would note both have comparable capital intensity.

Income Quality Ratio (OCF / Net Income)

0.39

Decreased from previous period

Below 0.5x 3141.T's 1.22. Michael Burry would expect an eventual correction in reported profits.

Operating Cash Flow-to-Sales Ratio

1.88%

Decreased from previous period

75–90% of 3141.T's 2.15%. Bill Ackman would seek improvements in how sales turn into cash.

Select Chart Metric:

3349.T Cash Flow Analysis - Compare Against 3141.T

Comparison against 3141.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Operating Cash Flow per Share

23.81

Decreased from previous period

OCF/share above 1.5x 3141.T's 9.88. David Dodd would verify if a competitive edge drives superior cash generation.

Free Cash Flow per Share

3.66

Decreased from previous period

FCF/share above 1.5x 3141.T's 1.66. David Dodd would confirm if a strong moat leads to hefty cash flow.

Capex-to-Operating Cash Flow

84.62%

Increased from previous period

Similar Capex/OCF to 3141.T's 83.22%. Walter Schloss would note both have comparable capital intensity.

Income Quality Ratio (OCF / Net Income)

0.39

Decreased from previous period

Below 0.5x 3141.T's 1.22. Michael Burry would expect an eventual correction in reported profits.

Operating Cash Flow-to-Sales Ratio

1.88%

Decreased from previous period

75–90% of 3141.T's 2.15%. Bill Ackman would seek improvements in how sales turn into cash.

Select Chart Metric: